RT Journal Article
T1 Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project.
A1 Santos García, Diego
A1 Blázquez-Estrada, Marta
A1 Calopa, Matilde
A1 Escamilla-Sevilla, Francisco
A1 Freire, Eric
A1 García Ruiz, Pedro J
A1 Grandas, Francisco
A1 Kulisevsky, Jaime
A1 López-Manzanares, Lydia
A1 Martínez Castrillo, Juan Carlos
A1 Mir, Pablo
A1 Pagonabarraga, Javier
A1 Pérez-Errazquin, Francisco
A1 Salom, José María
A1 Tijero, Beatriz
A1 Valldeoriola, Francesc
A1 Yáñez, Rosa
A1 Avilés, Arantxa
A1 Luquín, María-Rosario
K1 Parkinson’s disease
K1 Spain
K1 diagnosis
K1 economic impact
K1 epidemiology
K1 management
K1 mortality
K1 quality of life
K1 treatment
AB Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
SN 2076-3425
YR 2021
FD 2021-07-31
LK https://hdl.handle.net/10668/26504
UL https://hdl.handle.net/10668/26504
LA en
DS RISalud
RD Apr 5, 2025